Top 10 Pulmão

OSWALDO CRUZ, SBOC
America/Sao_Paulo GMT -3

Description

Topics & Speakers:

 

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial,

Gustavo Prado

 

COVID-19 in patients with thoracic malignancies,

Gilberto Lopes

 

Erlotinib Versues Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage III A-N2 EGFR-Mutant Non-Small-Cell Lung Cancer,

Eldsamira Mascarenhas

 

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer,

Gilberto de Castro

 

Nivolumab plus Ipilimumab in Advanced Non-Small-Cel Lung Cancer,

William N. William Jr.

 

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort,

Gustavo Schvartsman

 

Pemetrexed, Bevacizumab, or the Combination as Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer,

Mauro Zukin

 

Ramucirumab plus erlotnib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer,

Luiz H. Araujo

 

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer,

Vladmir Lima

 

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer

Clarissa Mathias

Carlos Henrique Teixeira

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial, COVID-19 in patients with thoracic malignancies, Erlotinib Versues Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage III A-N2 EGFR-Mutant Non-Small-Cell Lung Cancer, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer, Nivolumab plus Ipilimumab in Advanced Non-Small-Cel Lung Cancer, STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort, Pemetrexed, Bevacizumab, or the Combination as Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer, Ramucirumab plus erlotnib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer, Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer, Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer

Português

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES
 

Speakers

Cheng Tzu Yen, Gustavo Prado, Gilberto Lopes, Eldsamira Mascarenhas, Gilberto de Castro, William N. William Jr., Gustavo Schvartsman, Mauro Zukin, Luiz H. Araujo, Vladmir Lima, Clarissa Mathias

 
 
 
 

Download the Agenda

Search for our next event. See you soon!

Subscribe to get news on all upcoming events

who%20goals_edited.png

DocMeeetings

Social Media

  • Twitter DocMeetings
  • Instagram DocMeetings
  • Facebook ícone social
  • LinkedIn ícone social

contact us

Adress

Sao Paulo, SP - Brazil

© 2020 by Docmeetings - A DocMeetings.com Company
Site Managed by:
QUALITY Soluções Web
1996-2020 "24 years inspiring technology"
Top 10 Pulmão